The ASX-listed investment manager smashed analysts’ expectations thanks to the stellar performance of its growth house.

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

Brooks Running has a mega list of popular shoes on sale for less than $100. Shoppers can grab huge deals on shoes like the ...

Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

Brooks Running often refreshes its markdown page but in a rare deal, the Hyperion is seeing a markdown as low as $84.

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.